Multidrug-resistant tuberculosis
tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).
Tuberculosis is caused by infection with the bacterium Mycobacterium tuberculosis. Almost one in four people in the world are infected with TB bacteria. Only when the bacteria become active do people become ill with TB. Bacteria become active as a result of anything that can reduce the person's immunity, such as HIV, advancing age, diabetes or other immunocompromising illnesses. TB can usually be treated with a course of four standard, or first-line, anti-TB drugs (i.e., isoniazid, rifampicin, pyrazinamide and ethambutol).
However, beginning with the first antibiotic treatment for TB in 1943, some strains of the TB bacteria developed resistance to the standard drugs through genetic changes (see mechanisms). This process accelerates if incorrect or inadequate treatments are used, leading to the development and spread of multidrug-resistant TB (MDR-TB). Incorrect or inadequate treatment may be due to use of the wrong medications, use of only one medication (standard treatment is at least two drugs), or not taking medication consistently or for the full treatment period (treatment is required for several months).
Treatment of MDR-TB requires treatment with second-line drugs, (i.e., fluoroquinolones, aminoglycosides, and others), which in general are less effective, more toxic and much more expensive than first-line drugs.
The public source identifies “Multidrug-resistant tuberculosis” as tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs. This brief keeps that definition visible, then builds a research path around Multidrug-resistant, tuberculosis and resistant.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Multidrug-resistant tuberculosis”, the useful work is to connect “tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 10, 2026. The linked authority identifier is Q866602. The Library of Congress control number is sh2007003767. None of the 1 selected statements returned an explicit reference. The first chronological checks are 1943.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Multidrug-resistant tuberculosis”, its source revision and the description used here.
- Expand the search: follow Multidrug-resistant tuberculosis primary sources, Multidrug-resistant tuberculosis archive and Multidrug-resistant research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Multidrug-resistant tuberculosis”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Multidrug-resistant tuberculosis” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.